Effect of alpha-mangostin on olanzapine-induced metabolic disorders in rats.
Anti-oxidants
Leptin
Liver
Mangostin
Metabolic syndrome
Obesity
Olanzapine
Weight gain
Journal
Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
03
07
2021
accepted:
11
01
2022
entrez:
3
6
2022
pubmed:
4
6
2022
medline:
4
6
2022
Statut:
ppublish
Résumé
As olanzapine has side effects such as weight gain and metabolic disorders, and alpha-mangostin has been shown to control metabolic disorders, the effects of alpha-mangostin on metabolic disorders induced by olanzapine were investigated in this study. Obesity was induced in female Wistar rats by daily administration of olanzapine (5 mg/kg/day, IP, 14 days). Rats were divided into 6 groups:1) vehicle (control); 2) olanzapine (5 mg/kg/day); 3,4,5) olanzapine+ alpha-mangostin (10, 20, 40 mg/kg/day, IP); 6) alpha-mangostin (40 mg/kg/day). Weight changes were measured every 3 days and food intake was assessed every day. Systolic blood pressure, plasma levels of blood sugar, triglycerides, total cholesterol, HDL, LDL, leptin, oxidative stress markers (MDA, GSH), AMPK, and P-AMPK protein levels in liver tissue were assessed on the last day of the study. Administration of olanzapine significantly increased weight gain, food intake, blood pressure, triglycerides, LDL, blood sugar, leptin, and MDA in rat liver tissue and also decreased GSH, AMPK, and P-AMPK in liver tissue compared with the control group. Different doses of alpha-mangostin significantly reduced weight gain, food intake, systolic blood pressure, triglycerides, LDL, blood sugar, leptin, and MDA. Also, they significantly increased GSH, AMPK, and P-AMPK in liver tissue compared with the olanzapine group. Olanzapine increases leptin levels, food intake, and weight, induces oxidative stress, decreases the levels of AMPK and P-AMPK proteins in liver tissue, and causes metabolic disorders. But, alpha-mangostin reduces the negative effects of olanzapine by activation of AMPK.
Identifiants
pubmed: 35655598
doi: 10.22038/IJBMS.2022.58734.13047
pmc: PMC9124543
doi:
Types de publication
Journal Article
Langues
eng
Pagination
198-207Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
J Agric Food Chem. 2015 Sep 30;63(38):8399-406
pubmed: 26368128
Phytother Res. 2020 Dec;34(12):3211-3225
pubmed: 32592535
Lancet. 2013 Sep 14;382(9896):951-62
pubmed: 23810019
Psychoneuroendocrinology. 2014 Apr;42:153-64
pubmed: 24636512
Prev Chronic Dis. 2006 Apr;3(2):A42
pubmed: 16539783
Eur J Pharmacol. 2006 Dec 3;551(1-3):112-5
pubmed: 17046744
Pharmacol Res. 2015 Nov;101:74-85
pubmed: 26218604
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3456-9
pubmed: 17360666
J Clin Psychopharmacol. 2002 Aug;22(4):424-6
pubmed: 12172344
Iran J Basic Med Sci. 2019 Dec;22(12):1476-1482
pubmed: 32133067
J Agric Food Chem. 2013 Apr 24;61(16):3891-900
pubmed: 23578285
J Clin Psychiatry. 1999 Nov;60(11):767-70
pubmed: 10584766
Iran J Basic Med Sci. 2021 Jan;24(1):3-16
pubmed: 33643564
N Engl J Med. 2005 Sep 22;353(12):1209-23
pubmed: 16172203
J Psychopharmacol. 2006 Jan;20(1):75-9
pubmed: 16204328
Daru. 2020 Jun;28(1):45-55
pubmed: 31792920
Iran J Basic Med Sci. 2020 Nov;23(11):1374-1381
pubmed: 33235693
Transl Psychiatry. 2018 Nov 29;8(1):258
pubmed: 30498208
Mol Biol Rep. 2020 Oct;47(10):7583-7592
pubmed: 32929650
Int J Mol Sci. 2018 May 01;19(5):
pubmed: 29723988
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):945-54
pubmed: 20452386
Arch Biochem Biophys. 1959 May;82(1):70-7
pubmed: 13650640
Phytother Res. 2020 Sep;34(9):2192-2202
pubmed: 32222004
J Med Entomol. 2010 Mar;47(2):249-57
pubmed: 20380307
Biomed Pharmacother. 2017 Aug;92:726-731
pubmed: 28586744
Phytother Res. 2017 Aug;31(8):1173-1182
pubmed: 28656594
Drug Des Devel Ther. 2014 Nov 06;8:2193-211
pubmed: 25395836
Int J Mol Sci. 2011;12(5):3117-32
pubmed: 21686173
Nutr Neurosci. 2012 Sep;15(5):13-9
pubmed: 23232053
Neuropsychopharmacology. 2007 Feb;32(2):289-97
pubmed: 17035934
Trends Endocrinol Metab. 2010 Nov;21(11):643-51
pubmed: 20846876
Pharmacol Ther. 2010 Sep;127(3):210-51
pubmed: 20493213
J Exp Pharmacol. 2020 Jan 28;12:27-38
pubmed: 32095085
Oncotarget. 2017 Jul 18;8(29):47425-47439
pubmed: 28537893
Xenobiotica. 2016;46(4):369-78
pubmed: 26364812
Cell Physiol Biochem. 2018;50(4):1216-1229
pubmed: 30355932
Indian J Psychiatry. 2006 Jan;48(1):39-42
pubmed: 20703413
Iran J Basic Med Sci. 2019 May;22(5):460-468
pubmed: 31217924
Arch Med Res. 2011 Apr;42(3):244-51
pubmed: 21722822
Iran J Basic Med Sci. 2016 Dec;19(12):1258-1270
pubmed: 28096957
Pain. 1983 Jun;16(2):109-110
pubmed: 6877845
J Pharmacol Exp Ther. 2008 Sep;326(3):905-11
pubmed: 18567835
Drugs. 2001;61(1):111-61
pubmed: 11217867
J Neuroendocrinol. 2008 Jul;20(7):942-51
pubmed: 18445126
J Psychopharmacol. 2019 Oct;33(10):1303-1316
pubmed: 31294646
Schizophr Res. 2009 May;110(1-3):103-10
pubmed: 19321312
Ther Adv Psychopharmacol. 2014 Feb;4(1):30-6
pubmed: 24490028
Arch Gen Psychiatry. 2012 Dec;69(12):1226-37
pubmed: 22868896
Trends Mol Med. 2008 Dec;14(12):539-49
pubmed: 18977694
Phytother Res. 2020 Aug;34(8):1798-1811
pubmed: 32097990
Anal Biochem. 1978 May;86(1):271-8
pubmed: 655387
Biomed Res Int. 2015;2015:785826
pubmed: 25950001
Naunyn Schmiedebergs Arch Pharmacol. 2016 Sep;389(9):931-49
pubmed: 27178264
Saudi Med J. 2006 Nov;27(11):1703-5
pubmed: 17106545
Evid Based Complement Alternat Med. 2015;2015:740238
pubmed: 25873982
Neuropharmacology. 2012 Mar;62(3):1391-400
pubmed: 21376062
Phytother Res. 2021 Jul;35(7):3558-3574
pubmed: 33590943
Iran J Basic Med Sci. 2020 Oct;23(10):1261-1267
pubmed: 33149857
Eur Neuropsychopharmacol. 2012 May;22(5):364-73
pubmed: 21982116